Clinical trial Recruiting at 1 site Observational Ages 18 and up

Monitoring glucose levels in critically ill patients

Official title: Continuous Subcutaneous Glucose Monitoring: A Descriptive Study of Its Use in Critical Patients

Run by Universidad Europea de Madrid · NCT06234787 · Data updated 2026-11-12

This study looks at how often critically ill patients in the ICU experience low blood sugar and how using continuous glucose monitors can help improve their care.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment245 (estimated)
SponsorUniversidad Europea de Madrid
Academic / other
Locations1 site (Madrid)
StatusRecruiting
StartedNovember 30, 2023
Main results expectedDecember 1, 2027
Study endsDecember 1, 2027
Registry record updatedFebruary 5, 2024
Trial IDNCT06234787 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include critically ill patients in the ICU who are undergoing insulin treatment and have a CGM sensor.

Probably not a fit

Patients who are not admitted to the ICU or those who cannot provide information on CGM due to technical issues may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the incidence of hypoglycemic events in critically ill patients admitted to the ICU at HLA Moncloa Hospital over a four-year period. It will document occurrences of low glucose levels detected by continuous subcutaneous glucose monitoring (CGM) and describe the characteristics of patients receiving CGM sensors. The study seeks to understand the impact of glycemic control on patient outcomes and the actions taken in response to detected hypoglycemic events.

Why it matters

Potential benefit: If successful, this study could improve glycemic management in critically ill patients, potentially reducing the incidence of hypoglycemic events and associated complications.

How similar studies have gone: Other studies have shown varying success with continuous glucose monitoring in critical care settings, indicating potential benefits but also highlighting the complexity of glycemic management.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* The study will be conducted in patients admitted to the ICU of HLA Moncloa Hospital over four years. Patients admitted to the ICU, undergoing insulin treatment, and having a CGM sensor.
* Patients who sign the voluntary consent to participate in the study (Annex 2). If the participant is not in full physical or intellectual capacity to provide their signature on the informed consent, the responsible investigator will request such consent from their direct family member or the person legally designated to make decisions on their behalf regarding health matters. This measure is taken to ensure that the participant\'s rights are respected, and the integrity of the consent process is maintained, even in situations where their decision-making capacity may be compromised.

Exclusion Criteria:

* Patients from whom information on CGM cannot be obtained for technical reasons.

Where it's running

  • Hospital Universitario HLA Moncloa
    Madrid, Spain
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.